Table 3

Results from the panel mixed logit model
Attributes and levels Estimate (95% confidence interval) P value Standard deviation
Constant 0.90*** (0.62 to 1.17) 0.00
Efficacy (1% risk reduction) 0.07*** (0.05 to 0.08)a 0.00 1.19*** (1.06 to 1.30)
Cost per month (€1) -0.05*** (–0.04 to –0.06)a 0.00 1.24*** (1.09 to 1.39)
Drug administration (reference level: weekly oral tablet)
 Monthly oral tablet 0.69*** (0.36 to 1.03) 0.00 0.92*** (0.65 to 1.19)
 Subcutaneous injection 3-monthly 0.16 (–0.09 to 0.42) 0.21 NSb
 Subcutaneous injection 6-monthly 0.75*** (0.44 to 1.07) 0.00 NS
 Intravenous injection 3-monthly -0.57** (–1.12 to –0.01) 0.05 2.62*** (2.04 to 3.20)
 Intravenous injection yearly 0.28 (–0.12 to 0.68) 0.17 1.56*** (1.17 to 1.94)
Side-effects (reference level: gastrointestinal disorders)
 Flu-like symptoms 0.97*** (0.76 to 1.18) 0.00 0.90*** (0.65 to 1.15)
 Skin reactions 0.63*** (0.41 to 0.85) 0.00 1.04*** (0.81 to 1.26)

Number of observations 3,822 (257 respondents × 15 choices, minus 33 missing values).

Pseudo-R2 = 0.42; log-likelihood = –2,456.03; Akaike information criterion = 1.29.

aFor the coefficients of efficacy and cost to you, exp(β) is shown. The standard deviation of the log-normal distribution is reported. bNot significant and not included in the final model. **P < 0.05. ***P < 0.01.

Hiligsmann et al.

Hiligsmann et al. Arthritis Research & Therapy 2014 16:R36   doi:10.1186/ar4465

Open Data